Velicept Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2015-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.velicept.com
A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)
Phase 2
Completed
- Conditions
- Overactive Bladder
- Interventions
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Velicept Therapeutics, Inc.
- Target Recruit Count
- 1413
- Registration Number
- NCT03594058
- Locations
- 🇺🇸
Velicept Investigative Site - Doral(2), Doral, Florida, United States
🇺🇸Velicept Investigative Site - Hialeah, Hialeah, Florida, United States
🇺🇸Velicept Investigative Site - Tucson, Tucson, Arizona, United States
Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women
Phase 2
Completed
- Conditions
- Overactive Bladder
- Interventions
- First Posted Date
- 2018-03-23
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Velicept Therapeutics, Inc.
- Target Recruit Count
- 438
- Registration Number
- NCT03475706
- Locations
- 🇺🇸
Velicept Investigative Site - Kalamazoo, Kalamazoo, Michigan, United States
🇺🇸Velicept Investigative Site - Los Angeles, Los Angeles, California, United States
🇺🇸Velicept Investigative Site - Boston, Boston, Massachusetts, United States
Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects, Overactive Bladder
- Interventions
- First Posted Date
- 2016-10-19
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- Velicept Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02938507
© Copyright 2025. All Rights Reserved by MedPath